Abstract

<div>Abstract<p><b>Purpose:</b> Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a central role in tumor progression. We investigated whether CAFs can regulate tumor-infiltrating lymphocytes (TILs) and their role in tumor immunosuppression.</p><p><b>Experimental Design:</b> A total of 140 cases of esophageal cancer were analyzed for CAFs and CD8<sup>+</sup> or forkhead box protein 3 (FoxP3<sup>+</sup>) TILs by IHC. We analyzed cytokines using murine or human fibroblasts and cancer cells. Murine-derived fibroblasts and cancer cells were also inoculated into BALB/c or BALB/c-<i>nu/nu</i> mice and the tumors treated with recombinant IL6 or anti-IL6 antibody.</p><p><b>Results:</b> CD8<sup>+</sup> TILs and CAFs were negatively correlated in intratumoral tissues (<i>P</i> < 0.001), whereas FoxP3<sup>+</sup> TILs were positively correlated (<i>P</i> < 0.001) in esophageal cancers. Cocultured Colon26 cancer cells and fibroblasts resulted in accelerated tumor growth in BALB/c mice, along with decreased CD8<sup>+</sup> and increased FoxP3<sup>+</sup> TILs, compared with cancer cells alone. <i>In vitro</i>, IL6 was highly secreted in both murine and human cancer cell/fibroblast cocultures. IL6 significantly increased Colon26 tumor growth in immune-competent BALB/c (<i>P</i> < 0.001) with fewer CD8<sup>+</sup> TILs than untreated tumors (<i>P</i> < 0.001), whereas no difference in BALB/c-<i>nu/nu</i> mice. In contrast, FoxP3<sup>+</sup> TILs increased in IL6-treated tumors (<i>P</i> < 0.001). IL6 antibody blockade of tumors cocultured with fibroblasts resulted not only in regression of tumor growth but also in the accumulation of CD8<sup>+</sup> TILs in intratumoral tissues.</p><p><b>Conclusions:</b> CAFs regulate immunosuppressive TIL populations in the TME via IL6. IL6 blockade, or targeting CAFs, may improve preexisting tumor immunity and enhance the efficacy of conventional immunotherapies. <i>Clin Cancer Res; 24(19); 4820–33. ©2018 AACR</i>.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.